CII recognized Cadila among Top 50 Innovative Companies in India

Biocon Biologics recognized as an Asia IP Elite for 2023

Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list

Dr. Reddy's becomes first Indian pharma company to debut on the DJSI

Dr. Reddy's has been awarded 'Gold Medal' status by EcoVadis

Ami Organics inaugurates new API manufacturing facility

This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment

Merck and Moderna initiate Phase 3 study evaluating V940 (mRNA-4157) in combination with Keytruda for treatment of non-small cell lung cancer

The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)

Merck Animal Health receives positive CVMP opinion for an injectable formulation of Bravecto

The CVMP recommends the product for approval for the treatment and persistent killing of fleas

Sarclisa Phase 3 trial met primary endpoint of progression free survival with newly diagnosed multiple myeloma not eligible for transplant

Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone

Akums acquires new facility in Baddi to enhance tablet manufacturing capacity

his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.

Dr. Reddy's inks pact with Coya Therapeutics for development of sclerosis drug

Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya

Cupid acquires land parcel near Mumbai

The acquisition will enable Cupid Limited to amplify its production capacity by 1.5 times the existing output